Chronic renal failure (CRF) is a global threat to health in general and for developing countries in particular because therapy is expensive and lifelong. CRF not only increases the mortality and morbidity but also leads to adverse impact on the economy of the country. It represents a progressive irreversibledecline in the glomerular filtration rate (GFR). A common phenomenon inrenal failure is progressive renal function loss irrespective of the underlyingcause of the kidney disease. Objective: To evaluate the efficacy of Vajedi Basti along with Punarnavashtak Kwatha Ghanavati in Chronic Renal Failure. Methods: 30 patients of Chronic Renal Failure, irrespective of sex were randomly selected and open non comparative clinical trial was conducted. Vajedi Basti was given to patientsalong with the Punarnavashtak Kwatha Ghanavati which was administered for 3 months in dose 2 gm. BD with water after food. Serum Creatinine, BUN and meanGFR value were done initially and at the end of trial. Paired t test was used for statistical analysis. Results: After completion of study with relief in symptoms of Chronic Renal Failure there was also marked improvement inSerum Creatinine, BUN and mean GFR values. Highly significant results were observed. Conclusion: Vajedi Basti along with the Punarnavashtak Kwatha Ghanavati proved to be a promising line of treatment in Chronic Renal Failure. There was marked improvement in Serum Creatinine, BUN and mean GFR values. No side effects were seen during the study.
